Davenport & Co’s Theravance Biopharma TBPH Stock Holding History

Davenport & Co’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34,000	Closed	-$252K	–	1113
2021 Q3	$252K	Buy	+34,000	New	+$380K	﹤0.01%	911

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Davenport & Co's TBPH Position: Q4 2021 in Review

Davenport & Co sold out of Theravance Biopharma (TBPH) in Q4 2021, closing a stake of 34,000 shares — an estimated $252K sold.

Davenport & Co first reported a position in TBPH in Q3 2021 and held it in 1 quarter. The position peaked at $252K in Q3 2021. 116 funds tracked by Wall St. Rank hold TBPH as of Q4 2021.

Davenport & Co reported no remaining Theravance Biopharma position as of Q4 2021 after selling out during the quarter.
Davenport & Co sold 34,000 Theravance Biopharma shares in Q4 2021, an estimated $252K.
Davenport & Co first reported a position in Theravance Biopharma in Q3 2021 and held it in 1 quarter.
Davenport & Co's Theravance Biopharma position peaked at $252K in Q3 2021.
116 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2021.

Based on Davenport & Co's 13F filing for Q4 2021, filed 10 Feb 2022.